Pharmacology’s Krzysztof Palczewski provides key discovery for new therapy for patients with retinal degeneration diseases

Boston biopharmaceutical company licenses technology from Case Western Reserve University
Crain’s Cleveland Business: Case Western Reserve University reached a licensing agreement with Vision Medicines Inc., a Boston-based clinical-stage biopharmaceutical company developing therapies for patients suffering from retinal degeneration diseases. Krzysztof Palczewski, the John H. Hord Professor and chair of the Department of Pharmacology, made a key discovery that led to the therapy’s creation.